Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Security Researcher: Exchange Loses $300,000 to MEV Bot Due to Misconfiguration in 0x Contract Interaction

Security Researcher: Exchange Loses $300,000 to MEV Bot Due to Misconfiguration in 0x Contract Interaction

金色财经金色财经2025/08/14 04:26
Show original

According to Jinse Finance, a certain exchange lost approximately $300,000 in token fees to MEV bots due to a misconfiguration when interacting with 0xProject’s “swapper” contract. Venn Network security researcher and “X” user deeberiroz disclosed on Wednesday that the exchange interacted with the “swapper” smart contract of 0x, a decentralized peer-to-peer trading platform, even though this contract was never intended for token approval operations. The “swapper” contract provided by 0xProject is designed for executing token swaps. It is permissionless, allowing anyone to call it for any operation without ownership restrictions. However, it is not designed to receive token approvals, as doing so could expose funds to risk. The researcher noted that this design has previously led to known issues, such as incidents involving Zora airdrop claims on the BaseLayer2 network.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56